Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Senti-Scint
- Development stage
- Unknown
- Lead developer
- Medi-Radiopharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous, Peritumoral
01
Overview
Senti-Scint is a radiopharmaceutical cold kit developed by Medi-Radiopharma for the preparation of technetium-99m labeled human serum albumin (HSA) nanosized colloid. Upon reconstitution with a sterile solution of sodium 99mTc-pertechnetate, the agent forms a radioactive tracer used for sentinel lymph node mapping and lymphoscintigraphy. The nanosized colloid particles are designed to migrate through the lymphatic system following subcutaneous or peritumoral injection, where they are subsequently trapped within the sentinel lymph nodes. This localization allows for the diagnostic visualization and detection of these nodes using single-photon emission computed tomography (SPECT) or SPECT/CT imaging, primarily in patients with breast cancer or malignant melanoma to assist in surgical planning and staging.
- Brand names
- Senti-Scint
- Other names
- 99mTc-HSA nanosized colloidtechnetium (99mTc) human serum albumin nanosized colloidTc-99m HSA nanocolloidTc99m HSA nanocolloidTc 99m HSA nanocolloid
Beyond the preview
Go deeper on Senti-Scint.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senti-Scint.